Bioventix Share Discussion Threads

[stepone68] 01/5/2018 09:05

Dividend has, finally, arrived with iWeb. No explanation of what went wrong.

[igbertsponk] 30/4/2018 16:00

Can't keep a well-run company down.

[melton john] 30/4/2018 07:34

Smaller companies try harder, try X-O. Top man is Andrew Grant, always fixes problems which might arise.

[gsbmba99] 28/4/2018 08:30

Halifax are still claiming that they have yet to receive the cheque from the registrar. I think the probability that Halifax are telling the truth is extremely low. There must be an established electronic payment mechanism because the dividend has been paid by Halifax on the date of the payment in the past.

[stepone68] 26/4/2018 11:14

Back in 2016 I got in touch with both Bioventix and iDealing about the delay in receiving dividends. Back then iDealing told me they were waiting for the cheque to clear and it would be 11th November before that happened - payment date then was 30th September.

For Bioventix, Peter Harrison replied to say that brokers should be able to contact the registrar to arrange for future payments to be by BACS. It appears that iDealing must have done this, seems incredible that iWeb, who are part of a much larger organisation, can't do something similar. I'll be contacting them today to complain.

Cheers,
StepOne

[sharw] 26/4/2018 09:20

I have had an online chat with iWeb. They did not receive the cheque in the post. It beggars belief that in this era of crest a/cs dividend cheques are still sent this way. They have already spoken with the registrars and if iweb don't receive it by tomorrow the registrars will be issuing a new one.

[melton john] 25/4/2018 16:01

20th also on XO

[gsbmba99] 25/4/2018 15:57

Divi not received in my Halifax account. iWeb is Halifax subsidiary. Seems to be a Halifax issue.

[alter ego] 25/4/2018 12:46

got mine on 20th with HL

[stepone68] 25/4/2018 12:40

Anyone not got their divi yet? I have received mine with iDealing, but not in my iWeb account.

[gsbmba99] 18/4/2018 10:37

At the results presentation, Peter had said that Siemens were excited about the potential for high sensitivity Troponin to be used as a more regular test of cardiac disease monitoring/progression beyond just A&E. This research would appear to support this view. This, I believe, was done using the Abbott hsTnI test. "Higher hsTnI levels are associated with the underlying burden of coronary atherosclerosis, more rapid progression of CAD [coronary artery disease], and higher risk of all‐cause mortality and incident cardiovascular events." The clinical implications are interesting: 1) "High‐sensitivity cardiac troponin I is potentially a surrogate biomarker to monitor therapeutic responses in patients with coronary artery disease" and 2) "Whether interventions aimed at reducing its levels are associated with improved outcomes requires further investigation"

[stepone68] 29/3/2018 15:29

See what a difference a header update makes :-)

[igbertsponk] 29/3/2018 14:35

Happy reading like the share price again!

[strollingmolby] 28/3/2018 23:18

Not a problem, it had been neglected... Last two half years now added-in, and makes for happy reading.

[stepone68] 28/3/2018 21:17

Thanks, sorry, didn't mean to sound like I was nagging! Just that I like the '6 month segment' breakdown..

[strollingmolby] 28/3/2018 14:56

stepone, yes I should get to it in the coming days...

[stepone68] 27/3/2018 12:47

Is nobody updating the header here any more?

[igbertsponk] 27/3/2018 11:35

Soon be back to its deserved £30 at this rate!

[gsbmba99] 26/3/2018 17:57

A somewhat useful article post the FDA's Nov 17 Troponin meeting: Interesting to see that Singulex say they filed for approval in November (but haven't been cleared and are now behind the normal 3 month clearance curve). So, FDA not halting applications for approval but also not issuing any clarification and not clearing any applications.

[gsbmba99] 26/3/2018 16:10

Not in relation to something with a near term impact but, from the FY17 results: "On a longer term perspective, we continue to work with our partners in Norway on the secretoneurin (CardiNor & heart diagnostics) and amyloid projects (Pre Diagnostics & dementia). We have made exciting antibodies to contribute towards the scientific development of these projects and we look forward to developing the science of these long term projects over the coming years."

[igbertsponk] 26/3/2018 16:00

"commercial development of this exciting new product would not gear up until calendar year 2018"
Not sure I can ever remember such a positive word as "exciting" in a BVXP announcement. I suspect it means that we're in for a few more years of bumper performance.

[gsbmba99] 26/3/2018 15:48

The £770k relates to the period "1 July 2014 to 30 June 2017". So, 3 financial years but it probably has growth within that period so it could be something like £200k, £250k and £300k for instance. I haven't seen anything that states whether the royalty understatement relates to a royalty stream for which there is a continuing revenue expectation. It would be helpful to know that. If it doesn't relate to an expired revenue stream it's a nice recurring revenue uplift assuming the client can now calculate it correctly.

[stepone68] 26/3/2018 15:40

The 770k was over 4 years, so an extra 200k per year, say, missed off the previous 4 years accounts, and, assuming Siemens have improved their processes so that they don't miss these in the future, should have a positive impact going forward?

StepOne